Skip to main content

Table 2 Contingency table showing the breast tumors included in our study categorized according to the cutoff points established for each test (as described in Material and Methods).

From: Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer

- 32 2
+ 1 4